Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

未开盘 02-02 16:00:00 EST

83.07

+0.40

+0.48%

盘后83.07

+0.000.00%

19:00 EST

最高83.35	最低81.90	成交量178.89万
今开82.54	昨收82.67	日振幅1.75%
总市值134.55亿	流通市值133.74亿	总股本1.62亿
成交额1.48亿	换手率1.11%	流通股本1.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":83.07,"timestamp":1770066000000,"preClose":82.67,"halted":0,"volume":1788929,"hourTrading":{"tag":"盘后","latestPrice":83.07,"preClose":83.07,"latestTime":"19:00 EST","volume":75300,"amount":6255104.85,"timestamp":1770076833530,"change":0,"changeRate":0,"amplitude":0.004454},"delay":0,"changeRate":0.004838514576025057,"floatShares":161000000,"shares":161974393,"eps":-1.613241,"marketStatus":"未开盘","change":0.4,"latestTime":"02-02 16:00:00 EST","open":82.54,"high":83.35,"low":81.9,"amount":148368476.03015998,"amplitude":0.01754,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.613241,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770109200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":82.67,"preHourTrading":{"tag":"盘前","latestPrice":83.4,"preClose":82.67,"latestTime":"08:59 EST","volume":442,"amount":36607.536159999996,"timestamp":1770040756052,"change":0.73,"changeRate":0.00883,"amplitude":0.028426},"postHourTrading":{"tag":"盘后","latestPrice":83.07,"preClose":83.07,"latestTime":"19:00 EST","volume":75300,"amount":6255104.85,"timestamp":1770076833530,"change":0,"changeRate":0,"amplitude":0.004454},"volumeRatio":0.900151,"impliedVol":0.453,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/IONS","defaultTab":"news","newsList":[{"id":"1191518855","title":"Ionis Pharmaceuticals, Inc 有望获得1500万美元里程碑付款及高达30%的净销售额分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1191518855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191518855?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:04","pubTimestamp":1768997079,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc 近日迎来重大利好消息。根据最新合作协议条款，该公司已具备资格获取一笔高达1500万美元的里程碑付款。更值得关注的是，其特许权使用费结构将采用分层模式，最高可达产品净销售额的30%。这一商业安排凸显了Ionis Pharmaceuticals核心产品的市场潜力。对于Ionis Pharmaceuticals而言，这笔潜在收益将为其研发管线注入新的资金支持，同时强化公司在罕见病和精准医疗领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1145314898","title":"渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1145314898","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145314898?lang=zh_cn&edition=full","pubTime":"2026-01-13 00:11","pubTimestamp":1768234293,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准渤健公司针对脊髓性肌萎缩症的Spiranza®（Nusinersen）高剂量治疗方案。这一监管里程碑标志着该疗法在欧盟市场获得重要拓展，为患者群体提供更具灵活性的用药选择。\n此次获批的高剂量方案将进一步提升药物在临床实践中的应用价值，凸显渤健公司在神经科学治疗领域持续创新的战略布局。监管机构的认可也为该疗法在更广泛患者群体中的使用铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","BIIB","LU0109394709.USD","LU0234570918.USD","IE00B19Z9P08.USD","LU0889565916.HKD","BK4585","BK4588","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4533","IONS","IE00B894F039.SGD"],"gpt_icon":0},{"id":"1137439537","title":"Ionis合作伙伴葛兰素史克公布Bepirovirsen三期研究B-Well 1和B-Well 2积极顶线结果 该药物有望成为慢性乙肝首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1137439537","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137439537?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:18","pubTimestamp":1767770330,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc的合作伙伴葛兰素史克宣布，其针对慢性乙型肝炎的潜在首创药物Bepirovirsen，在三期临床研究B-Well 1和B-Well 2中取得了积极的顶线结果。这项关键进展标志着该疗法在追求功能性治愈慢性乙肝的道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1172421919","title":"Ionis宣布拟议可转换债券发行以再融资2026年可转换债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1172421919","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172421919?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:25","pubTimestamp":1763573107,"startTime":"0","endTime":"0","summary":"11月12日消息 - Ionis Pharmaceuticals Inc ::*IONIS宣布拟议可转换债券发行以再融资2026年可转换债券*IONIS PHARMACEUTICALS INC - 将发行7亿美元可转换债券，到期时间为2030年*IONIS PHARMACEUTICALS INC - 授予额外7000万美元债券的选择权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1158847363","title":"Dawnzera™（Donidalorsen）获得CHMP积极意见，推荐在欧盟批准治疗遗传性血管水肿（HAE）","url":"https://stock-news.laohu8.com/highlight/detail?id=1158847363","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158847363?lang=zh_cn&edition=full","pubTime":"2025-11-14 20:01","pubTimestamp":1763121688,"startTime":"0","endTime":"0","summary":"Dawnzera™（Donidalorsen）获得CHMP的积极意见，建议在欧盟批准用于治疗遗传性血管水肿（HAE）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1159503918","title":"Ionis Pharmaceuticals Inc：定价7亿美元的2030年到期0.00%可转换高级债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1159503918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159503918?lang=zh_cn&edition=full","pubTime":"2025-11-13 13:40","pubTimestamp":1763012431,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals Inc：定价7亿美元的2030年到期0.00%可转换高级债券","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1191555721","title":"Ionis Pharmaceuticals股价在盘后上涨3.2%；宣布拟定可转换债券发行以再融资2026年可转换票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1191555721","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191555721?lang=zh_cn&edition=full","pubTime":"2025-11-12 05:38","pubTimestamp":1762897106,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals股价在盘后上涨3.2%；宣布拟定可转换债券发行以再融资2026年可转换票据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1172347027","title":"Ionis Pharmaceuticals：预计产品REV将迎来增长，新增合作伙伴REV助力公司在2028年实现现金流持平","url":"https://stock-news.laohu8.com/highlight/detail?id=1172347027","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172347027?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:11","pubTimestamp":1761736303,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals：预计产品REV将迎来增长，新增合作伙伴REV助力公司在2028年实现现金流持平","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1123195233","title":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1123195233","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123195233?lang=zh_cn&edition=full","pubTime":"2025-09-18 19:41","pubTimestamp":1758195688,"startTime":"0","endTime":"0","summary":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B19Z9P08.USD","LU0320765992.SGD","LU0889565916.HKD","IONS","BK4588","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","LU0109394709.USD","BK4139","BIIB","BK4533","IE00B894F039.SGD"],"gpt_icon":0},{"id":"1135242848","title":"BMO将Ionis Pharmaceuticals评级从市场表现上调至跑赢大盘，目标价从40美元上调至70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135242848","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135242848?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:01","pubTimestamp":1756897303,"startTime":"0","endTime":"0","summary":"BMO将Ionis Pharmaceuticals的评级从市场表现上调至跑赢大盘，同时将目标价从40美元大幅上调至70美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1197561614","title":"Ionis Pharmaceuticals高管表示急性胰腺炎患者平均住院17天，支付方成本高昂","url":"https://stock-news.laohu8.com/highlight/detail?id=1197561614","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197561614?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:16","pubTimestamp":1756818976,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals高管表示，急性胰腺炎患者平均住院时间长达17天，这对支付方来说成本非常高昂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1180606351","title":"Ionis Pharmaceuticals高管：严重高甘油三酯血症适应症获批时将公布定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180606351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180606351?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:07","pubTimestamp":1756818424,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals公司高管表示，该公司将在其严重高甘油三酯血症治疗适应症获得监管批准时公布相关药物的定价信息。这一表态显示该公司正在为其治疗严重高甘油三酯血症的药物制定市场准入策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1120167759","title":"Ionis Pharmaceuticals高管表示Olezarsen有潜力为患者提供每月使用自动注射器自我给药的便利性 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1120167759","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120167759?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:56","pubTimestamp":1756817811,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals高管表示Olezarsen有潜力为患者提供每月使用自动注射器自我给药的便利性 - 电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1133437325","title":"Ionis Pharmaceuticals：Olezarsen治疗严重高甘油三酯血症患者的关键3期Core和Core2研究获得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133437325","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133437325?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:24","pubTimestamp":1756812253,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布，其药物Olezarsen在治疗严重高甘油三酯血症患者的关键3期Core和Core2研究中取得积极的顶线结果。这一研究成果为该公司在代谢性疾病治疗领域的发展提供了重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1123660220","title":"Ionis Pharmaceuticals：Olezarsen达到减少急性胰腺炎事件的次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123660220","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123660220?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:12","pubTimestamp":1756811553,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals：Olezarsen达到减少急性胰腺炎事件的次要终点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1197389364","title":"Ionis Pharmaceuticals宣布Olezarsen三期临床研究取得积极结果 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1197389364","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197389364?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:08","pubTimestamp":1756811300,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布其药物Olezarsen的三期临床研究取得积极结果，该消息通过SEC文件披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1126122455","title":"Dawnzera™（多尼达洛森）获美国批准，成为首个也是唯一的RNA靶向遗传性血管水肿预防治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1126122455","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126122455?lang=zh_cn&edition=full","pubTime":"2025-08-21 23:46","pubTimestamp":1755791181,"startTime":"0","endTime":"0","summary":"Dawnzera™（多尼达洛森）已在美国获得批准，成为首个也是唯一一款针对遗传性血管水肿的RNA靶向预防性治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2518070452","title":"Ionis Pharmaceuticals, Inc.盘中异动 大幅下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518070452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518070452?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:53","pubTimestamp":1741632820,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时53分，Ionis Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.00%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025340abf37261&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025340abf37261&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2516309676","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516309676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516309676?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:34","pubTimestamp":1740774847,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时34分，Ionis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.01%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010434079896c4aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010434079896c4aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2513270227","title":"Ionis Pharmaceuticals, Inc.2024财年实现净利润-4.54亿美元，同比减少24.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513270227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513270227?lang=zh_cn&edition=full","pubTime":"2025-02-23 00:00","pubTimestamp":1740240042,"startTime":"0","endTime":"0","summary":"2月23日，Ionis Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-4.54亿美元，同比减少24.04%；其中营业收入为7.05亿美元，同比减少10.53%，每股基本收益为-3.03美元。机构评级：截至2025年2月23日，当前有22家机构对Ionis Pharmaceuticals, Inc.目标价做出预测，其中目标均价为58.23美元，其中最低目标价为37.00美元，最高目标价为78.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000052a24fcc08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000052a24fcc08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionispharma.com","stockEarnings":[{"period":"1week","weight":0.0256},{"period":"1month","weight":0.0427},{"period":"3month","weight":0.1398},{"period":"6month","weight":1.0415},{"period":"1year","weight":1.6041},{"period":"ytd","weight":0.0501}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位，利用新药研发平台，公司研发了大量的一流药品。反义技术在基因学和药物之间打开了一条通道。凭着公司高效多产的药物研发平台，公司可以用反义药物拓展自身及其合作伙伴的药物种类，满足大量的药物需求。公司的策略是做公司最擅长的事--寻找独特的反义药物并开发这些药物，使其成为关键的临床值转折点。公司发明并进行新药早期研究，然后将药物授权给合作伙伴。公司通过把药物交给领先的制药公司进行后期开发来实现药物的最大价值，如Biogen Idec公司、百时美施贵宝公司、 健赞公司、赛诺菲公司、葛兰素史克公司和礼来制药公司。 该公司的旗舰产品 KYNAMRO，正朝着市场上家族性高胆固醇血症患者迈进。 该公司于1989年在美国加州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.020204},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.013272},{"month":3,"riseRate":0.3,"avgChangeRate":-0.028033},{"month":4,"riseRate":0.4,"avgChangeRate":0.018094},{"month":5,"riseRate":0.4,"avgChangeRate":-0.049558},{"month":6,"riseRate":0.8,"avgChangeRate":0.059464},{"month":7,"riseRate":0.8,"avgChangeRate":0.041363},{"month":8,"riseRate":0.5,"avgChangeRate":0.012224},{"month":9,"riseRate":0.5,"avgChangeRate":0.051342},{"month":10,"riseRate":0.2,"avgChangeRate":-0.026479},{"month":11,"riseRate":0.6,"avgChangeRate":0.097251},{"month":12,"riseRate":0.4,"avgChangeRate":0.002194}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}